This program will be broadcast live from the 2024 COA Community Oncology Conference in Orlando, Florida.
Program Description
The development of bispecific antibody (BsAb) therapies represents a significant advancement in cancer care for patients with non-Hodgkin lymphoma (NHL), offering more targeted and effective treatment strategies. BsAbs dual targeting of cancer cells while also engaging the immune system’s cytotoxic mechanisms enhances the specificity and effectiveness of the treatment, with clinical data demonstrating improved patient outcomes. The rapid growth of BsAbs within oncology treatment paradigms has been associated with barriers to care including serious treatment-related toxicities as well as logistical considerations. As the approval, availability, and use of BsAbs expands in the treatment of patients with NHL, the role of community pharmacists will expand both clinically and operationally. This program will present key considerations for community pharmacists and equip them to safely and effectively manage transitions of care, adverse events of BsAb therapy, and barriers to access and adherence.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: April 4, 2024
Expiration date: June 4, 2024
Time to complete activity: 0.75 hour
Learner level: Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Compare efficacy and safety data for current and investigational bispecific antibodies (BsAbs) for the treatment of follicular and diffuse large B-cell lymphomas
- Explore clinical and logistical challenges that impact the use of BsAbs in community settings
- Investigate methods that community oncology pharmacists can integrate into multidisciplinary initiatives to improve the safe and effective use of BsAbs
Sarah Profitt, PharmD, BCPS, BCOP
Clinical Pharmacy Specialist – Adult Malignant Hematology
Vanderbilt University Medical Center
Nashville, Tennessee
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hour (0.075 CEU) under the ACPE universal activity number 0290-0000-24-025-L01-P. The activity is available for CE credit through June 4, 2024.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Sarah Profitt, PharmD, BCPS, BCOP, has the following relevant financial relationships with commercial interests to disclose:
Consultant: Genentech, Inc, Rigel Pharmaceuticals, Inc, Eli Lilly and Company
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Amy H. Seung, PharmD, BCOP, FHOPA, CHCP; Amy L. Morris, PharmD, BCOP; Crissy Wilson; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms